{"schema_version":"1.0","type":"article","title":"$130 Billion in Six Months: Big Pharma Is Buying Time","url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.md","lang":"en","date":"2026-07-27","publish_at":"2026-07-27T08:00:00+08:00","updated_at":"2026-07-27","category":"商業分析系列","topic":"商業分析系列","tags":["biopharma M&A","Big Pharma","patent cliff","loss of exclusivity","Lilly","Merck","AbbVie","Gilead","GSK","Terns","Apogee","Arcellx","Tubulis","Nuvalent","Organon","CVR","milestones","biotech valuation"],"summary":"Biopharma M&A accelerated in the first half of 2026, but BioSpace's 52 deals and IQVIA's 42 deals cannot be combined. The deeper story is that patent cliffs are pushing Big Pharma to pay for measurable clinical time.","key_points":[],"facts":[],"sections":["The Difference Between 52 and 42 Is Not Merely Ten Deals","Drugmakers Are Buying a Patent Clock, Not a Story","Lilly Went Shopping, but the Count Is Nine, Not Eleven","Gilead and GSK Are Betting on Oncology Assets Near Commercialization","Even the Largest Deal Cannot Be Read from the Headline Alone","Why a Hot M&A Market Does Not End the Biotech Winter","What Should Readers in Taiwan Watch?","Conclusion: $130 Billion Is Really a Purchase of Time","References","Disclaimer"],"references":[{"title":"Verification cutoff: July 19, 2026.","source":"","date":"","url":""},{"title":"[BioSpace","source":"H1 2026 M&A count and methodology]","date":"","url":"https://www.biospace.com/business/biopharma-strikes-50-m-as-deals-in-h1-led-by-lillys-25b-spend"},{"title":"[IQVIA","source":"Biopharma M&A: Mid-year 2026 update]","date":"","url":"https://www.iqvia.com/locations/emea/blogs/2026/07/biopharma-ma-mid-year-2026-update"},{"title":"[PwC","source":"US Deals 2026 midyear outlook]","date":"","url":"https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html"},{"title":"[Merck and Terns","source":"Transaction agreement]","date":"","url":"https://www.merck.com/news/merck-to-acquire-terns-pharmaceuticals-inc-expanding-its-hematology-pipeline-with-tern-701-a-novel-candidate-for-chronic-myeloid-leukemia-cml/"},{"title":"[Merck","source":"Completion of Terns acquisition]","date":"","url":"https://www.merck.com/news/merck-completes-acquisition-of-terns-pharmaceuticals-inc/"},{"title":"[AbbVie and Apogee","source":"Transaction announcement]","date":"","url":"https://investors.abbvie.com/news-releases/news-release-details/abbvie-acquire-apogee-therapeutics-deepening-immunology"},{"title":"[Gilead","source":"Completion of Arcellx acquisition]","date":"","url":"https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel"},{"title":"[Gilead","source":"Completion of Tubulis acquisition]","date":"","url":"https://investors.gilead.com/news/news-details/2026/Gilead-Sciences-Completes-Acquisition-of-Tubulis-Further-Strengthening-Oncology-Portfolio/default.aspx"},{"title":"[GSK and Nuvalent","source":"Transaction agreement]","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/"},{"title":"[GSK","source":"Completion of Nuvalent acquisition]","date":"","url":"https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/"},{"title":"[Organon and Sun Pharma","source":"Definitive agreement]","date":"","url":"https://www.organon.com/news/sun-pharma-signs-definitive-agreement-to-acquire-organon/"}],"images":[{"alt":"BioSpace and IQVIA use different inclusion rules, so 52 transactions and 42 transactions cannot be combined","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/01-dataset-methodology.webp"},{"alt":"Patent cliffs increase the value of assets that are closer to readout, filing, review or launch","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/02-buying-time-before-patent-cliff.webp"},{"alt":"Six representative transactions occupy different states, from announcement and closing to early clinical development and FDA review","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/03-six-deals-six-states.webp"},{"alt":"Upfront cash, milestones, CVRs and closing conditions allocate different parts of transaction risk","url":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/04-how-deal-terms-allocate-risk.webp"}],"cover_image":"https://drugnews.com.tw/assets/articles/h1-2026-biopharma-ma-buying-time-en/cover-en.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-27）。$130 Billion in Six Months: Big Pharma Is Buying Time。https://drugnews.com.tw/articles/2026-07-27-h1-2026-biopharma-ma-buying-time-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-07-27-h1-2026-biopharma-ma-buying-time.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}